Genmab EPS - Earnings per Share 2009-2021 | GNMSF

Genmab annual and quarterly earnings per share history from 2009 to 2021. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Genmab EPS for the quarter ending September 30, 2021 was $0.21, a 83.04% decline year-over-year.
  • Genmab EPS for the twelve months ending September 30, 2021 was $5.27, a 59.25% decline year-over-year.
  • Genmab 2020 annual EPS was $11.06, a 116.88% increase from 2019.
  • Genmab 2019 annual EPS was $5.1, a 35.7% increase from 2018.
  • Genmab 2018 annual EPS was $3.76, a 39.27% increase from 2017.
Genmab Annual EPS
2020 $11.06
2019 $5.10
2018 $3.76
2017 $2.70
2016 $2.86
2015 $1.87
2014 $0.94
2013 $0.40
2012 $-1.83
2011 $-2.35
2010 $-1.27
2009 $-1.49
2008 $-4.23
2007 $-1.72
Genmab Quarterly EPS
2021-09-30 $0.21
2021-06-30 $0.75
2021-03-31 $2.69
2020-12-31 $1.61
2020-09-30 $1.26
2020-06-30 $7.58
2020-03-31 $0.60
2019-12-31 $3.49
2019-09-30 $1.23
2019-06-30 $0.20
2019-03-31 $0.18
2018-06-30 $0.67
2018-03-31 $0.53
2017-12-31 $1.95
2017-09-30 $-0.01
2017-06-30 $0.73
2017-03-31 $0.04
2016-12-31 $2.01
2016-09-30 $0.46
2016-06-30 $0.41
2016-03-31 $-0.03
2015-12-31 $0.94
2015-09-30 $0.34
2015-06-30 $0.04
2015-03-31 $0.55
2014-12-31 $0.00
2014-09-30 $0.47
2014-06-30 $-0.08
2014-03-31 $0.33
2013-12-31 $0.00
2013-09-30 $0.02
2013-06-30 $-0.09
2013-03-31 $0.25
2012-12-31 $0.00
2012-09-30 $-0.21
2012-06-30 $-0.01
2012-03-31 $-0.27
2011-12-31 $0.00
2011-09-30 $-1.49
2011-06-30 $-0.33
2011-03-31 $-0.47
2010-12-31 $-0.31
2010-09-30 $-0.07
2010-06-30 $-0.35
2010-03-31 $-0.54
2009-12-31 $0.28
2009-09-30 $-0.44
2009-06-30 $-0.54
2009-03-31 $-0.79
2008-12-31 $-1.92
2008-06-30 $-1.38
2008-03-31 $-0.95
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $22.506B $1.549B
Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage. Genmab A/S is based in Copenhagen V, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69